Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Float 10,190,900...COVID 19 breakthrough...OTC PINK: (QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also known as COVID-19. The results showed no signs of toxicity in any of the patients involved in the study who were given the drug Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
Float 10,190,900...COVID 19 breakthrough...OTC PINK: (QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also known as COVID-19. The results showed no signs of toxicity in any of the patients involved in the study who were given the drug Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
Here we go, this could go parabolic if this volume stays up.. If the toe-rag investors jump in with this float it will be one for the record books..
Outstanding Shares
52,286,970
02/05/2021
Restricted
22,086,248
02/05/2021
Unrestricted
30,200,722
02/05/2021
Held at DTC
Not Available
Float
10,190,900
11/25/2019
Medolife Rx Announces Positive Results in Clinical Safety Study on Its Polarized Drug Candidate for the Treatment of COVID-19
BURBANK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also known as COVID-19. The results showed no signs of toxicity in any of the patients involved in the study who were given the drug Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
The study, which was conducted in Santo Domingo of the Dominican Republic under the supervision of medical principal investigators, was conducted on over 500 patients, where data from one group of patients was used in the Company’s FDA pre-IND filing. Each patient was given Escozine® sublingually four times a day. During and after administration, a complete blood count (CBC) was conducted on each patient where the researchers measured various parameters to evaluate if the drug candidate was safe, such as hemoglobin (Hb), hematocrit (HCT), and red blood cells (RBCs) levels. There were no significant differences observed before or after administration. Additionally, there were no significant differences observed in white blood cells (WBCs), neutrophils, lymphocytes, monocytes, or eosinophils, concluding that the drug candidate was safe and non-toxic.
“A successful safety study is a pivotal step in the clinical development program for a new drug candidate and we could not be more enthusiastic about our results,” said Medolife CEO Dr. Arthur Mikaelian. “While our near-term goal is to work with the Ministry of Environment of The Dominican Republic to bring this drug to market, we are able to use this data in our programs around the world, including with our submissions to the United States Food and Drug Administration. While there is significant research that suggests the potential therapeutic benefits of extracted scorpion peptide, when paired with our proprietary polarization technology that increases efficacy and bioavailability in the body, we believe our product Escozine® could be a true breakthrough in the field of medicine with applications in a variety of focus areas and indications.”
The Company is currently involved in various clinical studies on Escozine® around the world. It is seeking product registration in the Dominican Republic for treatment of COVID-19 where this study took place, while simultaneously seeking approval in the United States, where it has filed data on Escozine® with the US Food and Drug Administration (FDA) as a Pre-Investigational New Drug (PIND #150335) as a COVID-19 therapeutic. Registration in the Dominican Republic would act as a proof-of-concept on the drug that would propel it forward in its path to market.
Medolife’s patented polarization technology increases the potency of single molecules and complex compounds. This technology is already used in various Medolife products, ranging from supplements to drug candidates.
Eye opening news, lets see what the followup is.
Medolife Rx Announces Positive Results in Clinical Safety Study on Its Polarized Drug Candidate for the Treatment of COVID-19
BURBANK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also known as COVID-19. The results showed no signs of toxicity in any of the patients involved in the study who were given the drug Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
The study, which was conducted in Santo Domingo of the Dominican Republic under the supervision of medical principal investigators, was conducted on over 500 patients, where data from one group of patients was used in the Company’s FDA pre-IND filing. Each patient was given Escozine® sublingually four times a day. During and after administration, a complete blood count (CBC) was conducted on each patient where the researchers measured various parameters to evaluate if the drug candidate was safe, such as hemoglobin (Hb), hematocrit (HCT), and red blood cells (RBCs) levels. There were no significant differences observed before or after administration. Additionally, there were no significant differences observed in white blood cells (WBCs), neutrophils, lymphocytes, monocytes, or eosinophils, concluding that the drug candidate was safe and non-toxic.
“A successful safety study is a pivotal step in the clinical development program for a new drug candidate and we could not be more enthusiastic about our results,” said Medolife CEO Dr. Arthur Mikaelian. “While our near-term goal is to work with the Ministry of Environment of The Dominican Republic to bring this drug to market, we are able to use this data in our programs around the world, including with our submissions to the United States Food and Drug Administration. While there is significant research that suggests the potential therapeutic benefits of extracted scorpion peptide, when paired with our proprietary polarization technology that increases efficacy and bioavailability in the body, we believe our product Escozine® could be a true breakthrough in the field of medicine with applications in a variety of focus areas and indications.”
The Company is currently involved in various clinical studies on Escozine® around the world. It is seeking product registration in the Dominican Republic for treatment of COVID-19 where this study took place, while simultaneously seeking approval in the United States, where it has filed data on Escozine® with the US Food and Drug Administration (FDA) as a Pre-Investigational New Drug (PIND #150335) as a COVID-19 therapeutic. Registration in the Dominican Republic would act as a proof-of-concept on the drug that would propel it forward in its path to market.
Medolife’s patented polarization technology increases the potency of single molecules and complex compounds. This technology is already used in various Medolife products, ranging from supplements to drug candidates.
Besides play-caking with us he still has an international mining company on his plate. Hellowww, mining companies take enormous amounts of work and some time, but it is time well spent doing nothing if you already have your position.
If you are bored with nothing to do go to the company web site and read the mission statement, then go to OTC markets website for this ticker and read the mission statement....shazammmm!
If anyone is tired of waiting then someone is sitting, waiting for your sell order.... time for some bid support, I'll take em.
no sir +178.1620%. This is not my first rodeo.
yea so.. some toe-rag pumper hit this ticker.. it is a public company anyone can buy stock. Please a lack of understanding does not give anyone the right to be a legend in their own mind.
which STHC board... board of directors or bored of investors
Fidelity is not penny friendly, they only want your money to be handled by them.
Charles Schwabb, Ameritrade and Interactive Brokers are my penny players of choice..in that order.
now I see why they are doing the offering
This result will provide the foundation for which we can propel our research into humans, which we have already begun doing in the Dominican Republic and other countries around the world. This study data was also used in our pre-investigational new drug filing with the US Food and Drug Administration (FDA).”
This drug candidate utilizes Medolife’s patented polarization technology, which increases the potency of single molecules and complex compounds. This technology is already used in various Medolife products, ranging from supplements to drug
Synergy update 3/12/21.......................................
Wrapping up EMDF (XL Rent, Inc.) and have done elections which will be posted to NV SOS today.
Actually that is the cleanest way for a company to raise money, and creates a loyal long term shareholder base. HOWEVER, it usually costs about $600.00 to convert paper to tradable shares and not many brokers do it any more.
If you could afford to burn $40 or $50K on a company like this and you had faith in it why not grab some shares at a discount. That has been a very successful strategy for many in the past.
I think we see a massive tax bill if we do nothing until December then sell just a few.
ogalde bogalde.. this will be one saweet ride...
Market Cap Market Cap
4,357,625
03/12/2021
Outstanding Shares
42,513,415
11/01/2006
It is the purity that makes this discovery a high value asset. Plus the fact that it is open pit... easy peazy... I just want to see the amount and depth of overburden, that will tell us when we start to hit pay-dirt and should see revenues in the same quarter.
ok so let me get this right, the company is almost out of shares in the treasury so there is a program in place for you to buy a made up currency to fund this company..
what part of that makes investment sense
no sir, I speak only the truth.
reverse split within 6 months''''
Authorized Shares
2,000,000,000
03/12/2021
Outstanding Shares
1,933,685,840
03/12/2021
at .07 they have $4,900,000 left in the treasury to do what, build what bikes, cars EV blow up dolls.
If I speak the truth do not delete my messages.
So sorry, this is a balanced board, maybe you do not want to know you threw your money away but there will be someone who smartens up
Do your own research.
to bring some clarity so that maybe one young investor does not loose his cash flow
Big deal:: an loi to look into something.yea right
There is too much money to be made if you don't get suckered into companies run by known mob bosses
Day Gain
+14,934.50 (+7.33%)
Total Gain
+135,696.49 (+163.54%)
ALYI...Shameless Penny Stock FRAUD. Alright the gloves come off here...
I make one statement to protect naive investors and it gets deleted,, welcome to scum-ville.
From over 20 years of experience
this company is run by a mob boss who has suckered investors in on two other companies that failed.
this company makes press releases weekly to milk retail investors, they are all fluff
If your hard earned money is in this stock ask yourself, is it emotion or common sense that keeps you here?
Total Un-restricted: 25,843,616......................kaboom one day soon
Float way too high
Float 3,573,164,755 07/30/2020
Authorized Shares 4,993,000,000
03/09/2021
Outstanding Shares 4,353,272,336
03/09/2021
the outstanding is almost up to the authorized, so reverse split or raise the authorized...
I don't see any upside with this share structure
bang, got my 09's .. maybe that was all the bid support needed
What are you talking about, a bankrupt dark company with 1.4 billion shares out..................... good god go get a job
It's still a dark shell with hope springing eternal amongst the nut job traders of the world.
I wish you well on your stock journey. However holding on to hope with no plans for survival is a good way to shorten your journey.
I could care less what your opinions are, there is certain criteria for success in this market and this stock is a proven scam and will not go anywhere, in time you will see.
Enjoy your ride.
what the hell is an ICO?
Usually drilling companies are sub contracted and will work for any mining company wanting to poke holes..
Usually.
As someone that has been in the markets and survived quite well over the past 20 years I have been watching the paper fluff digitized as press releases from this company for some time now.
I am sure there are many new investors that are clinging to this hope stock for reasons that were dreamed up internally however the one thing you must always look at..
The share structure.............. there is none, all the shares have been sold out of the treasury and there are no more shares to use for payment of company expenses............ that means... a reverse split within the next two months
Wake up little grasshoppers....
Authorized Shares
2,000,000,000
03/06/2021
Outstanding Shares
1,913,685,840
03/06/2021
Disclaimer: I do not own this stock nor would I ever own this stock, I put my faith in people behind the companies.. do the due.
NO DO NOT DO THAT>>>> As a retail investor that owns shares before a merger making any waves will just cause the company lawyer to initiate a reverse split to get rid of us..
Remember we are the lowest form of scum in the reverse merger process.. WE PROVIDE NOTHING TO THE DEAL JUST LIKE A PARASITE WE ARE ALONG FOR THE RIDE.
I once purposely did a 100/1 reverse to get rid of some "activist retail investors"
know your place, do not make waves.
Time-frame to go public was always Q2 of 2021. The work involved before that date is done primarily by lawyers and accountants and both of them have a shut the hell up mentality.
You will not hear anything until after an sec filing. And if retail investors start hounding the company, remember they hold the power over whether we tag along or not.
not before doing a 10 for 1 reverse split
most of the shares have been sold out of the treasury
Authorized Shares 900,000,000 02/24/2021
Outstanding Shares 787,809,137 02/24/2021
Still a long way to go here, getting current will probably come in a flurry but expect delays, there usually is at least one. Timeline from the company did say 2nd quarter this year to be public.. still I think it is a dice roll and could be optimistic.
The story is moving in the right direction..
If that NI 43-101 does get published next month then professional money managers and mining mutual funds that invest in startup miners are going to be all over this.
There is nothing greater than riding a stock carried by professional money, they do not sell on an upward blip and hold with a 2 to 5 year time frame...
this is going to get very interesting and a lot of eyes are going to go buggy.
The chart action for this stock is called:
]
]
]
]
]
]
A FAT GIRLS PANTIES ON A WINDY CLOTHESLINE...
It does not matter, it is the story and is it progressing.